Montana is currently home to 259 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Billings, Missoula, Great Falls and Kalispell. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Community Hospital of Anaconda, Anaconda, Montana
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213
Recruiting
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation preve... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana
Conditions: Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162
Recruiting
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary
Register for Updates
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
NCT05050084
Recruiting
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivatio... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Billings Clinic Cancer Center, Billings, Montana
Conditions: Prostate Adenocarcinoma
Register for Updates
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Billings Clinic Cancer Center, Billings, Montana
Conditions: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
NCT04134260
Recruiting
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechani... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Billings Clinic Cancer Center, Billings, Montana
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268
Recruiting
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana
Conditions: Grade II Meningioma, Intracranial Meningioma
Register for Updates
Wakȟáŋyeža (Little Holy One)
NCT04201184
Recruiting
The overall goal of this study is to develop, adapt and evaluate an intergenerational prevention intervention, named "Wakȟáŋyeža (Little Holy One)," with Native American caregivers on a Northern Plains reservation and the caregivers' 2-to-5-year-old children. The intervention aims to: 1) reduce symptoms of historical trauma and everyday stress among parents/caregivers, 2) improve parenting, and 3) improve children's emotional and behavioral developmental outcomes to reduce future risk for suicid... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Fort Peck Tribal Head Start, Poplar, Montana
Conditions: Suicide, Trauma, Psychological, Parenting
Register for Updates
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
NCT05251727
Recruiting
To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: St. Vincent Frontier Cancer Center, Billings, Montana
Conditions: Chemotherapy-induced Peripheral Neuropathy
Register for Updates
Internet-Behavioral Cough Suppression Therapy
NCT05770401
Recruiting
The goal of this randomized, placebo-controlled, clinical trial is to develop and test the efficacy of an Internet-based behavioral intervention for refractory chronic cough. The main questions it aims to answer are: What are the best recruitment pathways to find people living with refractory chronic cough in Montana? Is Internet-Behavioral Cough Suppression Therapy (iBCST) efficacious? Do iBCST participants find it satisfactory? Is using Hyfe research app to monitor cough frequency feasible in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: University of Montana, Missoula, Montana
Conditions: Cough, Chronic Disease
Register for Updates
Impella Real-World Surveillance of Patients Using Sodium Bicarbonate
NCT05820451
Recruiting
The population enrolled in this study are all subjects who received an Impella in which a bicarbonate-based purge solution was used.
Gender:
All
Ages:
All
Trial Updated:
01/29/2024
Locations: Providence St. Patrick, Missoula, Montana
Conditions: Cardiogenic Shock, High Risk PCI
Register for Updates
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949
Recruiting
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Billings Clinic Cancer Center, Billings, Montana
Conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Register for Updates